...
首页> 外文期刊>JAMA dermatology >Association of Retinoic Acid Receptor β Gene With Onset and Progression of Lichen Sclerosus–Associated Vulvar Squamous Cell Carcinoma
【24h】

Association of Retinoic Acid Receptor β Gene With Onset and Progression of Lichen Sclerosus–Associated Vulvar Squamous Cell Carcinoma

机译:视黄酸受体β基因的结合与地衣硬化外阴鳞状细胞癌的发作和进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

RARβ ) tumor-suppressor gene is involved in the onset and/or progression of LS-VSCC. Design, Setting, and Participants ? The case-control study, conducted at University-Hospital of Ferrara, Italy, included 20 LS-VSCC (mean [SD] age, 75 [3] years) and 20 cancer-associated vulvar LS (caVLS; mean [SD] age, 62 [11] years) formalin-fixed embedded tissue specimens, 20 cancer-free vulvar LS (cfVLS), and 20 normal skin fresh specimens from diagnostic biopsies and women surgically treated for nonmalignant skin lesions, respectively. RARβ gene expression and promoter methylation were investigated in LS-VSCC and caVLS adjacent to VSCC specimens, and in cfVLS and normal skin specimens, as controls, by RT-Q real-time polymerase chain reaction (PCR) analysis, and sequencing of PCR-amplified bisulfite-treated DNA. c-Jun expression, an RARβ pathway–related gene, was also investigated. Main Outcomes and Measures ? RARβ expression, correlation with its promoter methylation and c-Jun expression, and association with onset or progression of LS-VSCC. Results ? In LS-VSCC, RARβ messenger RNA was 3.4-, 3.6-, and 4.8-fold lower than in caVLS ( P ?=?.001), cfVLS ( P ?=?.005), and normal skin ( P ??.001), respectively. The RARβ mRNA levels were similar in caVLS, cfVLS, and normal skin. The RARβ promoter was hypermethylated in 18 (90%) of 20 LS-VSCC, 11 (55%) of 20 cfVLS, 10 (50%) of 20 caVLS, and 5 (25%) of 20 in the normal skin group. The degree of methylation of RARβ promoter was higher in LS-VSCC, ranging from 5 to 9 (full promoter methylation) CpGs methylated, than in caVLS ( P ?=?.02), cfVLS ( P ?=?.03), or normal skin ( P ??.001), which was up to 5 CpGs methylated. Importantly, 0 of 8 LS-VSCC with 5 to 6 CpGs methylated and 5 (63%) of 8 LS-VSCC with 7 to 8 CpGs methylated were from patients with lymph node metastasis at diagnosis, respectively, whereas there were 2 of 2 (100%) LS-VSCC samples with 9 CpG methylated from patients with lymph node metastasis at diagnosis and subsequent recurrence. In LS-VSCC c-Jun mRNA was 4.3-, 1.4-, and 2.6-fold higher than in caVLS ( P ??.001), cfVLS ( P ?=?.001), and normal skin ( P ??.001), respectively. The expression of c-Jun was similar in caVLS, cfVLS, and normal skin. Conclusions and Relevance ? Hypermethylation-induced RARβ down-expression was associated with LS-VSCC and correlates with the upregulation of c-Jun . The degree of methylation of RARβ promoter increased with the malignancy of LS-VSCC. Therefore, RARβ gene dysregulation may play a role in progression of LS-VSCC, and RARβ promoter methylation status may be used as a prognostic marker in clinical treatment of patients with LS-VSCC.
机译:RARβ)肿瘤抑制基因参与LS-VSCC的发作和/或进展。设计,设置和参与者?在意大利法拉拉大学 - 医院进行的病例对照研究包括20 LS-VSCC(平均年龄,75 [3]年)和20个癌症相关的外阴LS(Cavls;意思是[SD]年龄, 62 [11]多年)福尔马林固定的嵌入式组织标本,20个无癌外阴LS(CFVL),以及来自诊断活检和女性的20个正常皮肤新鲜标本,分别用于非开始性皮肤病变。在LS-VSCC和邻近VSCC标本的脉冲中研究RARβ基因表达和启动子甲基化,并在CFVL和正常皮肤样品中,通过RT-Q实时聚合酶链反应(PCR)分析和PCR的测序扩增的双硫酸盐处理的DNA。还研究了C-JUM表达,raβ途径相关基因。主要成果和措施? RARβ表达,与其启动子甲基化和C-JUM表达的相关性,以及LS-VSCC发作或进展的关系。结果 ?在LS-VSCC中,比在脉冲中的3.4-,3.6-和4.8倍下,RARβ信使RNA(p?=Δ.001),CFVL(P?=Δ.005)和正常皮肤(p≤1。 ?.001)分别。脉搏,CFVL和正常皮肤中的RARβmRNA水平相似。 RARβ启动子以18(90%)的20LS-VSCC,11(55%)的20个CFVL,10(50%)的20个脉冲,10(50%)的20个脉,5(25%)的普通皮肤组。 LS-VSCC的RARβ启动子的甲基化程度较高,范围为5至9(全启动子甲基化)CpGs甲基化,而不是在脉冲(p?=β.02),CFVL(P?= 03),或正常的皮肤(p?& 001),其甲基化高达5个CPG。重要的是,8个LS-VSCC,5至6个CPGS甲基化和5(63%)的8 LS-VSCC,其中7至8个CPGS甲基化分别来自诊断患者淋巴结转移,而2个( 100%)LS-VSCC样品,9个CPG甲基化患者在诊断和随后的复发中均有淋巴结转移。在LS-VSCC C-JOM mRNA中比在脉冲中的4.3-,1.4-和2.6倍(p≤001),CFV1(P?=Δ.001)和正常皮肤(P?&lt ; 001)分别。 C-Jun的表达在Cavls,CFVL和正常皮肤中相似。结论和相关性?高甲基化诱导的RARβ下表达与LS-VSCC相关,并与C-Jun的上调相关。随着LS-VSCC的恶性肿瘤,RARβ启动子的甲基化程度增加。因此,RARβ基因失调可能在LS-VSCC的进展中发挥作用,并且RARβ启动子甲基化状态可以用作LS-VSCC患者的临床治疗中的预后标志物。

著录项

  • 来源
    《JAMA dermatology》 |2018年第7期|共5页
  • 作者单位

    Section of Pathology Oncology and Experimental Biology Department of Morphology Surgery and;

    Section of Dermatology and Infectious Diseases Department of Medical Sciences University of;

    Department of Medical Sciences University of Ferrara;

    Section of Pathology Oncology and Experimental Biology Department of Morphology Surgery and;

    Section of Pathology Oncology and Experimental Biology Department of Morphology Surgery and;

    Section of Dermatology and Infectious Diseases Department of Medical Sciences University of;

    Section of Dermatology and Infectious Diseases Department of Medical Sciences University of;

    Section of Anatomic Pathology Department of Morphology Surgery and Experimental Medicine;

    Section of Anatomic Pathology Department of Morphology Surgery and Experimental Medicine;

    Section of Pathology Oncology and Experimental Biology Department of Morphology Surgery and;

    Section of Pathology Oncology and Experimental Biology Department of Morphology Surgery and;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病学与性病学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号